Ionis Pharmaceuticals (IONS) vs Praxis Precision Medicines (PRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Praxis Precision Medicines (PRAX) has outperformed Ionis Pharmaceuticals (IONS) over the past year, gaining 385.4% versus a loss of 38.1%. Over five years, IONS leads with a +23.4% price change compared with -12.2% for PRAX. Ionis Pharmaceuticals is the larger company by market cap ($7.47 billion vs $7.31 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IONS | PRAX |
|---|---|---|
| Share price | $44.98 | $261.98 |
| Market cap | $7.47B | $7.31B |
| 1-day change | +3.87% | -0.60% |
| YTD return | -45.27% | -10.58% |
| 1-year return | -38.11% | +385.45% |
| 5-year return | +23.36% | -12.19% |
| EPS (TTM) | $-3.48 | $-12.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $943.71M | $0 |
| Revenue growth (YoY) | +33.83% | -100.00% |
| Net income (latest FY) | $-381.39M | $-303.27M |
| Gross margin | 98.31% | — |
| Operating margin | -40.45% | — |
| Net margin | -40.41% | — |
| 52-week high | $86.74 | $392.70 |
| 52-week low | $42.63 | $50.56 |
| Distance from 52-week high | -48.15% | -33.29% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +85.97% | +145.98% |
| Average volume | 3.51M | 408.88K |
| Shares outstanding | 166.18M | 27.92M |
| Employees | 1,480 | 168 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRAX has outperformed IONS by 423.6 percentage points over the past year.
- Ionis Pharmaceuticals grew revenue faster in its latest fiscal year (+33.83% vs -100.00%).
About Ionis Pharmaceuticals
IONS stock →Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
Health Care · Biotechnology: Pharmaceutical Preparations · 1,480 employees
About Praxis Precision Medicines
PRAX stock →Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees
IONS vs PRAX FAQ
Which is bigger, Ionis Pharmaceuticals or Praxis Precision Medicines?
Ionis Pharmaceuticals (IONS) is larger, with a market capitalization of $7.47B compared with $7.31B for Praxis Precision Medicines (PRAX).
Which stock has performed better over the past year, IONS or PRAX?
PRAX returned +385.45% over the past 12 months, compared with -38.11% for IONS (price return, excluding dividends). Past performance does not predict future results.
Are Ionis Pharmaceuticals and Praxis Precision Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.